HC Wainwright Reiterates Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)

HC Wainwright restated their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Thursday,Benzinga reports. They currently have a $75.00 price target on the biotechnology company’s stock.

SRPT has been the subject of several other research reports. Needham & Company LLC restated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Monday, January 27th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Evercore ISI cut their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target for the company. Finally, Robert W. Baird cut their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.82.

Sarepta Therapeutics Trading Down 3.6 %

NASDAQ SRPT opened at $103.06 on Thursday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 52 week low of $101.00 and a 52 week high of $173.25. The stock has a market capitalization of $9.84 billion, a PE ratio of 82.45 and a beta of 0.75. The firm has a 50 day moving average of $116.14 and a two-hundred day moving average of $122.76.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares in the company, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SRPT. Blue Trust Inc. raised its holdings in Sarepta Therapeutics by 896.5% in the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 511 shares during the period. International Assets Investment Management LLC raised its holdings in Sarepta Therapeutics by 59,222.7% in the third quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock valued at $9,483,000 after buying an additional 75,805 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Sarepta Therapeutics by 112.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,002 shares of the biotechnology company’s stock valued at $747,000 after buying an additional 3,180 shares during the period. State of Alaska Department of Revenue raised its holdings in Sarepta Therapeutics by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 11,035 shares of the biotechnology company’s stock valued at $1,378,000 after buying an additional 750 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in shares of Sarepta Therapeutics by 16.9% during the third quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 155 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.